Opus Genetics 향후 성장

Future 기준 점검 2/6

Opus Genetics은 연간 수입과 매출이 각각 30.9%와 48.1% 증가할 것으로 예상되고 EPS는 연간 35.1%만큼 증가할 것으로 예상됩니다.

핵심 정보

30.9%

이익 성장률

35.10%

EPS 성장률

Biotechs 이익 성장	25.4%
매출 성장률	48.1%
향후 자기자본이익률	n/a
애널리스트 커버리지	Good
마지막 업데이트	08 May 2026

최근 향후 성장 업데이트

Recent updates

분석 기사 • Feb 07

Revenues Not Telling The Story For Opus Genetics, Inc. (NASDAQ:IRD) After Shares Rise 43%

Opus Genetics, Inc. ( NASDAQ:IRD ) shareholders have had their patience rewarded with a 43% share price jump in the...

분석 기사 • Dec 11

Subdued Growth No Barrier To Opus Genetics, Inc. (NASDAQ:IRD) With Shares Advancing 27%

Despite an already strong run, Opus Genetics, Inc. ( NASDAQ:IRD ) shares have been powering on, with a gain of 27% in...

분석 기사 • Sep 09

Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Despite an already strong run, Opus Genetics, Inc. ( NASDAQ:IRD ) shares have been powering on, with a gain of 31% in...

분석 기사 • Jul 11

Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is Lacking

Opus Genetics, Inc.'s ( NASDAQ:IRD ) price-to-sales (or "P/S") ratio of 4.9x might make it look like a buy right now...

분석 기사 • May 19

Analysts Are Upgrading Opus Genetics, Inc. (NASDAQ:IRD) After Its Latest Results

Investors in Opus Genetics, Inc. ( NASDAQ:IRD ) had a good week, as its shares rose 7.4% to close at US$1.02 following...

분석 기사 • Apr 09

Slammed 25% Opus Genetics, Inc. (NASDAQ:IRD) Screens Well Here But There Might Be A Catch

Unfortunately for some shareholders, the Opus Genetics, Inc. ( NASDAQ:IRD ) share price has dived 25% in the last...

분석 기사 • Aug 19

Analyst Forecasts For Ocuphire Pharma, Inc. (NASDAQ:OCUP) Are Surging Higher

Celebrations may be in order for Ocuphire Pharma, Inc. ( NASDAQ:OCUP ) shareholders, with the analysts delivering a...

분석 기사 • Jul 24

Investors Still Aren't Entirely Convinced By Ocuphire Pharma, Inc.'s (NASDAQ:OCUP) Revenues Despite 30% Price Jump

Ocuphire Pharma, Inc. ( NASDAQ:OCUP ) shareholders have had their patience rewarded with a 30% share price jump in the...

분석 기사 • Jul 12

Companies Like Ocuphire Pharma (NASDAQ:OCUP) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

분석 기사 • May 02

Slammed 26% Ocuphire Pharma, Inc. (NASDAQ:OCUP) Screens Well Here But There Might Be A Catch

Unfortunately for some shareholders, the Ocuphire Pharma, Inc. ( NASDAQ:OCUP ) share price has dived 26% in the last...

분석 기사 • Mar 15

Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Ocuphire Pharma, Inc. ( NASDAQ:OCUP ) shareholders that were waiting for something to happen have been dealt a blow...

이익 및 매출 성장 예측

NasdaqCM:IRD - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	28	-67	-24	-27	10
12/31/2027	16	-56	-43	-44	13
12/31/2026	15	-49	-42	-61	15
12/31/2025	14	-50	-35	-35	N/A
9/30/2025	15	-68	-33	-33	N/A
6/30/2025	15	-58	-32	-32	N/A
3/31/2025	14	-59	-29	-29	N/A
12/31/2024	11	-58	-26	-26	N/A
9/30/2024	8	-27	-14	-14	N/A
6/30/2024	16	-14	-11	-11	N/A
3/31/2024	19	-11	-3	-3	N/A
12/31/2023	19	-10	-1	-1	N/A
9/30/2023	57	29	23	23	N/A
6/30/2023	45	19	22	22	N/A
3/31/2023	42	19	17	17	N/A
12/31/2022	40	18	14	14	N/A
9/30/2022	N/A	-22	-20	-20	N/A
6/30/2022	0	-22	-19	-19	N/A
3/31/2022	1	-24	-20	-20	N/A
12/31/2021	1	-57	-19	-19	N/A
9/30/2021	1	-69	-20	-18	N/A
6/30/2021	0	-66	-17	-16	N/A
3/31/2021	N/A	-61	-13	-12	N/A
12/31/2020	N/A	-25	-8	-7	N/A
9/30/2020	N/A	-8	-4	-4	N/A
6/30/2020	N/A	-9	-4	-4	N/A
3/31/2020	N/A	-8	-4	-4	N/A
12/31/2019	N/A	-6	-4	-4	N/A

애널리스트 향후 성장 전망

수입 대 저축률: IRD 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: IRD 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: IRD 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: IRD 의 수익(연간 48.1%)이 US 시장(연간 11.6%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: IRD 의 수익(연간 48.1%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: IRD의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/05/11 07:46
종가	2026/05/11 00:00
수익	2025/12/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Opus Genetics, Inc.는 14명의 분석가가 다루고 있습니다. 이 중 15명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
James Molloy	Alliance Global Partners
Madison Wynne El-Saadi	B. Riley Securities, Inc.
Kumaraguru Raja	Brookline Capital Markets

Opus Genetics 향후 성장

Future 기준 점검 2/6

핵심 정보

최근 향후 성장 업데이트

Consensus EPS estimates fall by 19%, revenue upgraded

Price target increased by 7.5% to US$9.50

Price target increased by 14% to US$8.83

Consensus EPS estimates fall by 16%, revenue upgraded

Price target increased by 13% to US$6.80

Consensus revenue estimates decrease by 18%, EPS upgraded

Recent updates

Opus Genetics Completes Enrollment In Cohort 1 Of Phase 1/2 OPGx-BEST1 Gene Therapy Study

Opus Genetics Announces Fda Acceptance of Opgx-Lca5 into Rare Disease Evidence Principles (Rdep) Program

CEO & Director notifies of intention to sell stock

Opus Genetics, Inc. announced that it expects to receive $159.928 million in funding from Oberland Capital Management LLC

High number of new directors

Consensus EPS estimates fall by 19%, revenue upgraded

CEO & Director notifies of intention to sell stock

Opus Genetics, Inc., Annual General Meeting, Apr 20, 2026

Price target increased by 7.5% to US$9.50

Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 14% to US$8.83

Opus Genetics, Inc. Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting

Opus Genetics, Inc. Announces Fda Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics, Inc. announced that it has received $25.000002 million in funding from Adage Capital Management, L.P., Trails Edge Capital Partners, LP, Marshall Wace LLP

Opus Genetics, Inc. announced that it expects to receive $25.000002 million in funding from Adage Capital Management, L.P., Trails Edge Capital Partners, LP, Marshall Wace LLP

Revenues Not Telling The Story For Opus Genetics, Inc. (NASDAQ:IRD) After Shares Rise 43%

New minor risk - Share price stability

Opus Genetics, Inc. Launches Gene Therapy Clinical Trial for Mertk-Related Retinitis Pigmentosa

Independent Chairman recently bought US$324k worth of stock

Subdued Growth No Barrier To Opus Genetics, Inc. (NASDAQ:IRD) With Shares Advancing 27%

Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease

Consensus EPS estimates fall by 16%, revenue upgraded

Third quarter 2025 earnings: EPS misses analyst expectations

Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease

Opus Genetics, Inc. Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease

Opus Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $23 million.

Price target increased by 13% to US$6.80

New major risk - Revenue and earnings growth

Opus Genetics, Inc. Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5

Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Opus Genetics, Inc. Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Opus Genetics, Inc. Appoints Rob Gagnon as Chief Financial Officer

Opus Genetics Inherited Retinal Disease Programs Featured At Medical and Industry Conferences in September

Opus Genetics, Inc. announced that it has received $3.5 million in funding

Consensus revenue estimates decrease by 18%, EPS upgraded

Opus Genetics Announces FDA Clearance of Ind Application for Gene Therapy Candidate OPGx-Best1

New major risk - Financial position

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Opus Genetics, Inc.'s (NASDAQ:IRD) Price Is Right But Growth Is Lacking

Opus Genetics, Inc. Announces Vega-3 Phase 3 Trial Met Its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics, Inc. Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

Consensus revenue estimates increase by 16%

Analysts Are Upgrading Opus Genetics, Inc. (NASDAQ:IRD) After Its Latest Results

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

Opus Genetics Announces One-Year Results from Adult Patients Treated in the Ongoing Phase 1/2 Study of Its Lead Gene Therapy Candidate OPGx-LCA5

Price target decreased by 13% to US$9.25

Slammed 25% Opus Genetics, Inc. (NASDAQ:IRD) Screens Well Here But There Might Be A Catch

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Consensus revenue estimates increase by 34%

Opus Genetics, Inc. has completed a Follow-on Equity Offering in the amount of $5.2 million.

Opus Genetics, Inc., Annual General Meeting, Apr 30, 2025

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Shareholder dilution

Opus Genetics, Inc. announced that it has received $1.500001 million in funding

Opus Genetics, Inc. has completed a Follow-on Equity Offering in the amount of $19.999999 million.

Opus Genetics, Inc. Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025

Opus Genetics, Inc. Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Opus Genetics, Inc. Announces First Pediatric Patient Was Dosed in its Ongoing Phase 1/2 Clinical Trial Evaluating OPGx-LCA5, its Investigational Gene Therapy for the Treatment of Leber Congenital Amaurosis

New major risk - Shareholder dilution

Opus Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $40 million.

CEO & Director recently bought US$98k worth of stock

Opus Genetics, Inc. to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024

CEO & Director recently bought US$101k worth of stock

Consensus revenue estimates increase by 40%, EPS downgraded

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 21% to US$13.67

Ocuphire Pharma, Inc. (NasdaqCM:OCUP) acquired Opus Genetics, Inc. for $25.8 million.

Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology